Voclosporin is a next-generation calcineurin inhibitor (CNI) used as an immunosuppressant, primarily in the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE). It is a structural analog of cyclosporine with enhanced potency and an improved pharmacokinetic profile, offering better efficacy and safety in long-term immunosuppression.
Voclosporin acts by inhibiting calcineurin, a phosphatase involved in T-cell activation, thereby reducing the immune-mediated inflammation and kidney damage seen in lupus nephritis.
Indications include:
∙ Treatment of active lupus nephritis in adult patients (approved in combination with background immunosuppressive therapy)
Impurities in voclosporin arise from its fermentation-derived origin (as with cyclosporine derivatives) and its complex semi-synthetic modifications. Given its chronic use and narrow therapeutic index, impurities must be tightly controlled as per ICH Q3A/B and pharmacopeial guidelines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Voclosporin is used in combination with immunosuppressants for the treatment of active lupus nephritis to reduce kidney inflammation and prevent progression to renal failure.
It inhibits the enzyme calcineurin, preventing activation of T-lymphocytes and thereby suppressing autoimmune activity and inflammation in the kidneys.
Unlike cyclosporine, voclosporin has a more predictable pharmacokinetic profile and generally does not require routine therapeutic drug monitoring, though renal function should be monitored regularly.
Yes, it is chemically stable under normal storage conditions, but like other peptides and CNIs, it should be protected from moisture, heat, and light to avoid degradation.
